© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Anteris Technologies Global Corp. (AVR) stock declined over -2.70%, trading at $8.30 on NASDAQ, down from the previous close of $8.53. The stock opened at $8.35, fluctuating between $8.23 and $8.45 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | 8.35 | 8.45 | 8.23 | 8.30 | 842.35K |
| Sep 09, 2026 | 8.58 | 8.74 | 8.50 | 8.53 | 681.94K |
| Sep 08, 2026 | 9.04 | 9.04 | 8.61 | 8.62 | 489.85K |
| Sep 04, 2026 | 8.66 | 9.10 | 8.66 | 9.04 | 362.9K |
| Sep 03, 2026 | 8.72 | 8.76 | 8.46 | 8.72 | 533.39K |
| Sep 02, 2026 | 8.50 | 8.86 | 8.49 | 8.59 | 470.41K |
| Sep 01, 2026 | 8.48 | 8.63 | 8.41 | 8.45 | 568.64K |
| Aug 31, 2026 | 8.66 | 8.74 | 8.43 | 8.61 | 755.01K |
| Aug 28, 2026 | 9.05 | 9.07 | 8.69 | 8.74 | 533.46K |
| Aug 27, 2026 | 8.95 | 9.37 | 8.91 | 8.97 | 469.45K |
| Aug 26, 2026 | 8.86 | 9.05 | 8.75 | 8.95 | 558.84K |
| Aug 25, 2026 | 8.86 | 8.96 | 8.72 | 8.89 | 515.18K |
| Aug 24, 2026 | 8.89 | 8.96 | 8.61 | 8.80 | 802.5K |
| Aug 21, 2026 | 9.41 | 9.41 | 8.95 | 8.98 | 566.65K |
| Aug 20, 2026 | 9.68 | 9.89 | 9.09 | 9.25 | 1.17M |
| Aug 19, 2026 | 9.72 | 10.10 | 9.39 | 9.83 | 1.26M |
| Aug 18, 2026 | 9.36 | 9.70 | 9.35 | 9.58 | 720.89K |
| Aug 17, 2026 | 9.27 | 9.60 | 9.21 | 9.42 | 487.1K |
| Aug 14, 2026 | 8.84 | 9.42 | 8.73 | 9.40 | 683.46K |
| Aug 13, 2026 | 8.85 | 9.13 | 8.84 | 8.93 | 446.99K |
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
| Employees | 174 |
| Beta | 0.73 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | -0.918% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Medical - Devices |